BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25740997)

  • 1. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
    Marjuki H; Mishin VP; Chesnokov AP; Jones J; De La Cruz JA; Sleeman K; Tamura D; Nguyen HT; Wu HS; Chang FY; Liu MT; Fry AM; Cox NJ; Villanueva JM; Davis CT; Gubareva LV
    J Infect Dis; 2015 Jan; 211(2):249-57. PubMed ID: 25124927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice.
    Tang J; Gao R; Liu L; Zhang S; Liu J; Li X; Fang Q; Feng Z; Xu C; Huang W; Wang D
    Sci Rep; 2021 Aug; 11(1):16293. PubMed ID: 34381119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
    Tang J; Zhang J; Zhou J; Zhu W; Yang L; Zou S; Wei H; Xin L; Huang W; Li X; Cheng Y; Wang D
    Virol J; 2019 Jul; 16(1):87. PubMed ID: 31266524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
    Yen HL; McKimm-Breschkin JL; Choy KT; Wong DD; Cheung PP; Zhou J; Ng IH; Zhu H; Webby RJ; Guan Y; Webster RG; Peiris JS
    mBio; 2013 Jul; 4(4):. PubMed ID: 23860768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets.
    Yen HL; Zhou J; Choy KT; Sia SF; Teng O; Ng IH; Fang VJ; Hu Y; Wang W; Cowling BJ; Nicholls JM; Guan Y; Peiris JS
    J Infect Dis; 2014 Dec; 210(12):1900-8. PubMed ID: 24951824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
    Sleeman K; Guo Z; Barnes J; Shaw M; Stevens J; Gubareva LV
    Emerg Infect Dis; 2013; 19(9):1521-4. PubMed ID: 23965618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
    Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
    PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza a virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Suzuki S; Shichinohe S; Itoh Y; Nakayama M; Ishigaki H; Mori Y; Ogata-Nakahara A; Nguyen CT; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antiviral Res; 2020 Jun; 178():104790. PubMed ID: 32272175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
    Tang J; Zhang SX; Zhang J; Li XY; Zhou JF; Zou SM; Bo H; Xin L; Yang L; Liu J; Huang WJ; Dong J; Wang DY
    Virology; 2020 Oct; 549():77-84. PubMed ID: 32853849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
    Hai R; Schmolke M; Leyva-Grado VH; Thangavel RR; Margine I; Jaffe EL; Krammer F; Solórzano A; García-Sastre A; Palese P; Bouvier NM
    Nat Commun; 2013; 4():2854. PubMed ID: 24326875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
    Gubareva LV; Sleeman K; Guo Z; Yang H; Hodges E; Davis CT; Baranovich T; Stevens J
    J Infect Dis; 2017 Sep; 216(suppl_4):S566-S574. PubMed ID: 28934455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCR for detection of oseltamivir resistance mutation in influenza A(H7N9) virus.
    Wang W; Song Z; Guan W; Liu Y; Zhang X; Xu L; Li J; Yuan Z; Hu Y
    Emerg Infect Dis; 2014 May; 20(5):847-9. PubMed ID: 24751348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
    Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
    J Virol; 2010 Aug; 84(16):8042-50. PubMed ID: 20519385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
    Gaymard A; Charles-Dufant A; Sabatier M; Cortay JC; Frobert E; Picard C; Casalegno JS; Rosa-Calatrava M; Ferraris O; Valette M; Ottmann M; Lina B; Escuret V
    J Antimicrob Chemother; 2016 Nov; 71(11):3036-3045. PubMed ID: 27432605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.
    Itoh Y; Shichinohe S; Nakayama M; Igarashi M; Ishii A; Ishigaki H; Ishida H; Kitagawa N; Sasamura T; Shiohara M; Doi M; Tsuchiya H; Nakamura S; Okamatsu M; Sakoda Y; Kida H; Ogasawara K
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4962-73. PubMed ID: 26055368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
    Wei YN; Zhang C; Chen Q; Guo Y
    Bing Du Xue Bao; 2014 Jul; 30(4):396-401. PubMed ID: 25272593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.
    Liu Q; Ma J; Strayer DR; Mitchell WM; Carter WA; Ma W; Richt JA
    Expert Rev Anti Infect Ther; 2014 Feb; 12(2):165-9. PubMed ID: 24350808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus.
    Qi Y; Fan H; Qi X; Zhu Z; Guo X; Chen Y; Ge Y; Zhao K; Wu T; Li Y; Shan Y; Zhou M; Shi Z; Wang H; Cui L
    Virus Res; 2014 Jan; 179():119-24. PubMed ID: 24211668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.